Analysts predict that Integra Lifesciences Holdings Corp (NASDAQ:IART) will report earnings per share of $0.07 for the current quarter, Zacks reports. Six analysts have made estimates for Integra Lifesciences’ earnings. The highest EPS estimate is $0.24 and the lowest is ($0.02). Integra Lifesciences posted earnings of $0.73 per share in the same quarter last year, which would suggest a negative year over year growth rate of 90.4%. The business is expected to issue its next quarterly earnings results on Wednesday, July 22nd.
On average, analysts expect that Integra Lifesciences will report full year earnings of $1.77 per share for the current fiscal year, with EPS estimates ranging from $1.37 to $2.11. For the next fiscal year, analysts forecast that the firm will post earnings of $2.73 per share, with EPS estimates ranging from $2.22 to $2.93. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Integra Lifesciences.
Integra Lifesciences (NASDAQ:IART) last announced its quarterly earnings results on Thursday, May 7th. The life sciences company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.63 by ($0.15). Integra Lifesciences had a net margin of 1.76% and a return on equity of 15.98%. The firm had revenue of $354.30 million for the quarter, compared to analyst estimates of $353.15 million. During the same period in the previous year, the firm posted $0.65 EPS. The company’s revenue was down 1.5% compared to the same quarter last year.
Several research analysts recently weighed in on IART shares. Piper Sandler reissued a “hold” rating and set a $58.00 price target on shares of Integra Lifesciences in a research report on Tuesday, April 7th. JMP Securities decreased their price target on Integra Lifesciences from $75.00 to $65.00 and set a “market outperform” rating for the company in a research note on Friday, May 8th. UBS Group decreased their target price on Integra Lifesciences from $65.00 to $55.00 and set a “neutral” rating for the company in a research note on Friday, May 8th. Citigroup assumed coverage on Integra Lifesciences in a report on Wednesday, May 27th. They issued a “neutral” rating and a $54.00 price target for the company. Finally, BidaskClub cut Integra Lifesciences from a “hold” rating to a “sell” rating in a report on Thursday, June 11th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $57.67.
Shares of NASDAQ IART traded down $0.65 during midday trading on Thursday, hitting $47.55. The stock had a trading volume of 5,471 shares, compared to its average volume of 605,124. The company has a quick ratio of 2.72, a current ratio of 4.09 and a debt-to-equity ratio of 1.25. Integra Lifesciences has a 1-year low of $34.21 and a 1-year high of $65.09. The company has a fifty day moving average price of $49.82 and a 200 day moving average price of $51.54. The company has a market capitalization of $4.13 billion, a price-to-earnings ratio of 153.65, a PEG ratio of 3.20 and a beta of 1.09.
In other Integra Lifesciences news, Director Stuart Essig sold 46,807 shares of the stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $52.08, for a total transaction of $2,437,708.56. Following the completion of the transaction, the director now owns 1,024,811 shares in the company, valued at $53,372,156.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Richard E. Caruso sold 600,000 shares of the stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $48.47, for a total transaction of $29,082,000.00. Following the transaction, the insider now owns 163,668 shares of the company’s stock, valued at approximately $7,932,987.96. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 663,995 shares of company stock valued at $32,428,706. 4.30% of the stock is owned by company insiders.
A number of hedge funds have recently added to or reduced their stakes in IART. Oxford Asset Management LLP increased its position in Integra Lifesciences by 36.9% during the 4th quarter. Oxford Asset Management LLP now owns 18,829 shares of the life sciences company’s stock valued at $1,097,000 after purchasing an additional 5,079 shares during the period. Advisor Group Inc. boosted its holdings in shares of Integra Lifesciences by 0.7% in the 4th quarter. Advisor Group Inc. now owns 33,610 shares of the life sciences company’s stock valued at $1,960,000 after buying an additional 243 shares in the last quarter. BNP Paribas Arbitrage SA boosted its holdings in shares of Integra Lifesciences by 969.4% in the 1st quarter. BNP Paribas Arbitrage SA now owns 74,208 shares of the life sciences company’s stock valued at $3,315,000 after buying an additional 67,269 shares in the last quarter. Twinbeech Capital LP acquired a new stake in Integra Lifesciences in the 1st quarter worth approximately $546,000. Finally, Amalgamated Bank boosted its stake in Integra Lifesciences by 11.7% in the 4th quarter. Amalgamated Bank now owns 16,353 shares of the life sciences company’s stock worth $953,000 after purchasing an additional 1,713 shares in the last quarter. Institutional investors and hedge funds own 83.82% of the company’s stock.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
See Also: Limitations of analyzing profit margin
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.